156 related articles for article (PubMed ID: 30942258)
1. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Sampaio RNR; Silva JSFE; Paula CDR; Porto C; Motta JOCD; Pereira LIA; Martins SS; Barroso DH; Freire GSM; Gomes CM
Rev Soc Bras Med Trop; 2019 Mar; 52():e20180292. PubMed ID: 30942258
[TBL] [Abstract][Full Text] [Related]
2. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
3. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
4. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
6. [Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Garcia Bustos MF; Barrio A; Parodi C; Beckar J; Moreno S; Basombrio MA
Medicina (B Aires); 2014; 74(5):371-7. PubMed ID: 25347898
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
9. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
[TBL] [Abstract][Full Text] [Related]
11. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
[TBL] [Abstract][Full Text] [Related]
14. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
15. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
Ventin F; Cincurá C; Machado PRL
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
[TBL] [Abstract][Full Text] [Related]
17. The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Tayyebi M; Darchini-Maragheh E; Layegh P; Kiafar B; Goyonlo VM
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009241. PubMed ID: 33739976
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
19. [Miltefosine or meglumine antimoniate in leishmaniasis].
Joob B; Wiwanitkit V
Medicina (B Aires); 2015; 75(2):130-1. PubMed ID: 25919881
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]